Want to see LAB full AI Analyst Report?
Revenue by Segment
Shows how sales are split across the company’s business lines (for example instruments, consumables and services, and major geographies). A larger share of consumables and services usually means steadier, higher-margin recurring revenue, while dependence on one-time instrument sales signals more revenue volatility and capital intensity — so the split reveals growth sustainability, margin profile, and exposure to demand cycles.2024 featured outsized, transient revenue from Somascan kits and large Services contracts that created a revenue bump; since 2025 that one‑time contribution has largely disappeared, revealing the company’s more stable recurring base in Consumables while Instruments remain cyclical and softer. For investors, treat the 2024 spike as nonrecurring risk—future growth depends on rebuilding services/project bookings or re‑commercializing Somascan, and on converting consumables demand into steady margin expansion rather than relying on episodic contract wins.
Date | Consumables | Instruments | Services & Other | Somascan Assay Kits |
|---|---|---|---|---|
Jun 30, 2026 | $9.38M | $5.13M | $5.59M | $0.00 |
Mar 31, 2026 | $10.98M | $4.47M | $5.69M | $0.00 |
Dec 31, 2025 | $8.95M | $8.46M | $6.39M | $0.00 |
Sep 30, 2025 | $8.71M | $5.09M | $5.75M | $0.00 |
Jun 30, 2025 | $10.46M | $5.21M | $6.09M | $0.00 |
Mar 31, 2025 | $14.45M | $7.78M | $18.56M | $0.00 |
Dec 31, 2024 | $14.68M | $8.54M | $23.50M | $0.00 |
Sep 30, 2024 | $14.01M | $5.59M | $25.38M | $0.00 |
Jun 30, 2024 | $8.85M | $7.05M | $15.04M | $6.27M |
Mar 31, 2024 | $10.41M | $4.90M | $21.95M | $8.28M |